Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Xue Zhang, Master
CONTACT
Yansong Li, Master
CONTACT
Lead
Shanghai Exuma Biotechnology Ltd.
With
This is a single-arm, open-label, phase 1 clinical study of C402-CD19-CAR cell therapy, to evaluate the safety, tolerability, efficacy of C402-CD19-CAR in subject with relapsed or refractory large B cell lymphoma. Subjects that meet inclusion criteria with positive CD19 (IHC ≥50% tumor cells or FACS ≥70% tumor cells) will receive C402-CD19-CAR treatment according to the modified 2+3+3 dose escalation design.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted